Click here to close
Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly.
We suggest using a current version of Chrome,
FireFox, or Safari.
Martin E
,
Aigrot MS
,
Grenningloh R
,
Stankoff B
,
Lubetzki C
,
Boschert U
,
Zalc B
.
???displayArticle.abstract???
BACKGROUND: Microglia are the resident macrophages of the central nervous system (CNS). In multiple sclerosis (MS) and related experimental models, microglia have either a pro-inflammatory or a pro-regenerative/pro-remyelinating function. Inhibition of Bruton's tyrosine kinase (BTK), a member of the Tec family of kinases, has been shown to block differentiation of pro-inflammatory macrophages in response to granulocyte-macrophage colony-stimulating factor in vitro. However, the role of BTK in the CNS is unknown.
METHODS: Our aim was to investigate the effect of BTK inhibition on myelin repair in ex vivo and in vivo experimental models of demyelination and remyelination. The remyelination effect of a BTK inhibitor (BTKi; BTKi-1) was then investigated in LPC-induced demyelinated cerebellar organotypic slice cultures and metronidazole-induced demyelinated Xenopus MBP-GFP-NTR transgenic tadpoles.
RESULTS: Cellular detection of BTK and its activated form BTK-phospho-Y223 (p-BTK) was determined by immunohistochemistry in organotypic cerebellar slice cultures, before and after lysophosphatidylcholine (LPC)-induced demyelination. A low BTK signal detected by immunolabeling under normal conditions in cerebellar slices was in sharp contrast to an 8.5-fold increase in the number of BTK-positive cells observed in LPC-demyelinated slice cultures. Under both conditions, approximately 75% of cells expressing BTK and p-BTK were microglia and 25% were astrocytes. Compared with spontaneous recovery, treatment of demyelinated slice cultures and MTZ-demyelinated transgenic tadpoles with BTKi resulted in at least a 1.7-fold improvement of remyelination.
CONCLUSION: Our data demonstrate that BTK inhibition is a promising therapeutic strategy for myelin repair.
Fig. 1. Increased BTK signal upon demyelination. Cerebellar organotypic slices from P9 Plp-GFP mouse (green oligodendrocytes and myelin) were maintained in culture (A) or subjected to LPC treatment at 6 days in vitro (DIV) for 16–17 h (B) before being immunostained for BTK (red) or p-BTK at DIV9. LPC treatment induced a demyelination (loss of GFP signal B, C) and a concomitant 8.5-fold increase in BTK signal (B, D). Similarly, p-BTK was also increased after LPC demyelination (E). (*p < 0.01; ***p < 0.0001). Scale bar = 100 μm.
Fig. 2. Detection of BTK in microglia and astrocytes. Cerebellar organotypic slices from P9 mouse, were maintained in culture and submitted to LPC treatment at DIV6 for 16–17 h. At DIV9 (i.e., peak of demyelination) immuno staining was performed for BTK (Red) and Iba1 (microglia, green). A–F: Small magnification of control (A–C), and after LPC-induced demyelination (D–F). G,H,J, and K: Higher magnification illustrating co-localisation of BTK and p-BTK in microglia labeled with Iba1 (G) or CD11-F4/80-CD68 (J) and astrocyte S100ß+ (H, K).L: An example of two cells co-expressing BTK and p-BTK. Note that BTK is more at the surface while p-BTK is more intracytoplasmic. I and M: Quantification of microglia and astrocytes expressing BTK (I) or p-BTK (M). Scale bars: A–F = 20 μm; G,H, J,K, and L = 10 μm.
Fig. 4. Cellular expression of BTK in Xenopus and dose–response of remyelination by BTKi (BTKi-1). A–F: Immunodetection of BTK in microglial cells, but not in oligodendrocytes. Coronal (A–C) or horizontal (D–F) tissue sections across the brain stem of stage 52–53 MBP-GFP-NTR tadpoles double-labeled with anti-BTK (A, C, D, F, red) and anti-GFP (B, C, oligodendrocytes, green) antibodies or isolectin IB4 (E, F, microglia, white). Note in A–C the complete exclusion of the two labels, illustrating absence of BTK in oligodendrocytes. (D–F) In contrast, all BTK+ cells were also IB4+. However, some IB4+ cells (white arrows) were not BTK+. G: Demyelination of stage 52–53 MBP-GFP-NTR tadpoles was achieved by 10 days exposure to metronidazole (10 mM) in the swimming water. Tadpoles were then returned to normal water or water containing increasing concentration of BTKi (BTKi-1) for 3 days. Remyelination was assayed by counting the number of GFP+ cells per optic nerve on day 3 of the repair period. Treatment of tadpoles with BTKi (BTKi-1) at concentrations ranging between 50 nM and 1 μM improved remyelination up to 1.7-foldcompared to spontaneous recovery (control) set as 1. (*p < 0.01; **p < 0.001). Scale bar in A–F = 20 μm.
Azum,
Kinetic study of the metal-dipeptide complex with ninhydrin facilitated by gemini (m-s-m) surfactant micelles.
2020, Pubmed
Azum,
Kinetic study of the metal-dipeptide complex with ninhydrin facilitated by gemini (m-s-m) surfactant micelles.
2020,
Pubmed
Bao,
Promotion of microglial phagocytosis by tuftsin stimulates remyelination in experimental autoimmune encephalomyelitis.
2019,
Pubmed
Barun,
Treatment of multiple sclerosis with anti-CD20 antibodies.
2012,
Pubmed
Binder,
Gas6 deficiency increases oligodendrocyte loss and microglial activation in response to cuprizone-induced demyelination.
2008,
Pubmed
Birgbauer,
Lysolecithin induces demyelination in vitro in a cerebellar slice culture system.
2004,
Pubmed
Block,
The role of the tec kinase Bruton's tyrosine kinase (Btk) in leukocyte recruitment.
2012,
Pubmed
Corneth,
BTK Signaling in B Cell Differentiation and Autoimmunity.
2016,
Pubmed
Gasperini,
Drugs in clinical development for multiple sclerosis: focusing on anti-CD20 antibodies.
2013,
Pubmed
Gatt,
Effect of bile salts on the hydrolysis of gangliosides, glycoproteins and neuraminyl-lactose by the neuraminidase of Clostridium perfringens.
1981,
Pubmed
Hartkamp,
Btk inhibition suppresses agonist-induced human macrophage activation and inflammatory gene expression in RA synovial tissue explants.
2015,
Pubmed
Haselmayer,
Efficacy and Pharmacodynamic Modeling of the BTK Inhibitor Evobrutinib in Autoimmune Disease Models.
2019,
Pubmed
He,
Ethyl pyruvate enhances spontaneous remyelination by targeting microglia phagocytosis.
2019,
Pubmed
Hendriks,
Targeting Bruton's tyrosine kinase in B cell malignancies.
2014,
Pubmed
Hendriks,
Drug discovery: New Btk inhibitor holds promise.
2011,
Pubmed
Ito,
Bruton's tyrosine kinase is essential for NLRP3 inflammasome activation and contributes to ischaemic brain injury.
2015,
Pubmed
Kappos,
Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial.
2011,
Pubmed
Karamita,
Therapeutic inhibition of soluble brain TNF promotes remyelination by increasing myelin phagocytosis by microglia.
2017,
Pubmed
Kaya,
Live imaging of targeted cell ablation in Xenopus: a new model to study demyelination and repair.
2012,
Pubmed
,
Xenbase
Keaney,
Inhibition of Bruton's Tyrosine Kinase Modulates Microglial Phagocytosis: Therapeutic Implications for Alzheimer's Disease.
2019,
Pubmed
Lloyd,
Central nervous system regeneration is driven by microglia necroptosis and repopulation.
2019,
Pubmed
Lloyd,
The pro-remyelination properties of microglia in the central nervous system.
2019,
Pubmed
López-Herrera,
Bruton's tyrosine kinase--an integral protein of B cell development that also has an essential role in the innate immune system.
2014,
Pubmed
Mangla,
Pleiotropic consequences of Bruton tyrosine kinase deficiency in myeloid lineages lead to poor inflammatory responses.
2004,
Pubmed
Mannioui,
The Xenopus tadpole: An in vivo model to screen drugs favoring remyelination.
2018,
Pubmed
,
Xenbase
Mannioui,
Conditional Demyelination and Remyelination in a Transgenic Xenopus laevis.
2019,
Pubmed
,
Xenbase
Mano,
Tec family of protein-tyrosine kinases: an overview of their structure and function.
1999,
Pubmed
Marron,
Toll-like receptor 4-, 7-, and 8-activated myeloid cells from patients with X-linked agammaglobulinemia produce enhanced inflammatory cytokines.
2012,
Pubmed
Menzfeld,
Tyrphostin AG126 exerts neuroprotection in CNS inflammation by a dual mechanism.
2015,
Pubmed
Montalban,
Placebo-Controlled Trial of an Oral BTK Inhibitor in Multiple Sclerosis.
2019,
Pubmed
Nam,
Ibrutinib suppresses LPS-induced neuroinflammatory responses in BV2 microglial cells and wild-type mice.
2018,
Pubmed
Pal Singh,
Role of Bruton's tyrosine kinase in B cells and malignancies.
2018,
Pubmed
Schwartz,
Macrophages and microglia in central nervous system injury: are they helpful or harmful?
2003,
Pubmed
Sekizar,
Remyelination by Resident Oligodendrocyte Precursor Cells in a Xenopus laevis Inducible Model of Demyelination.
2015,
Pubmed
,
Xenbase
Spassky,
The early steps of oligodendrogenesis: insights from the study of the plp lineage in the brain of chicks and rodents.
2001,
Pubmed
Whang,
Bruton's tyrosine kinase inhibitors for the treatment of rheumatoid arthritis.
2014,
Pubmed
Wight,
A myelin proteolipid protein-LacZ fusion protein is developmentally regulated and targeted to the myelin membrane in transgenic mice.
1993,
Pubmed
Zhang,
Central nervous system remyelination in culture--a tool for multiple sclerosis research.
2011,
Pubmed
